Clinical Trial Detail

NCT ID NCT01435395
Title Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

gliosarcoma

malignant glioma

glioblastoma multiforme

Therapies

Bevacizumab + Bortezomib + Temozolomide

Age Groups: adult

No variant requirements are available.